Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, ...

Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality.

RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Avadel Pharmaceuticals appointed Sev Melkonian as VP of patient services, distribution and reimbursement. Experity appointed ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Lastly, it saw an improvement in gross margins, thanks to lower royalty rates for Keytruda and Gardasil. 2024 was also the year where Merck looked at inorganic growth to expand its pharmaceuticals ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...